Skip to main content
      RT @VeenaRheumMD: Abstract 0444- Dr. Gupta
      ⭐️COVAD Study - ❗️18000 global pt survey looking at AE after COVID va

      Veena Katikineni VeenaRheumMD

      4 years ago
      Abstract 0444- Dr. Gupta ⭐️COVAD Study - ❗️18000 global pt survey looking at AE after COVID vaccination in Autoimmune disease 1227 IIM pt total- more injection site pain, headache, rash, fatigue in DM #ACR21 #ACRAmbassador https://t.co/s4Fc5c9Kln
      Blood Brain Barrier leakage correlates w/ CNS dysfunction in SLE - study by John Hanley of 78 SLE pts. CNS impaired in 4

      Dr. John Cush RheumNow

      4 years ago
      Blood Brain Barrier leakage correlates w/ CNS dysfunction in SLE - study by John Hanley of 78 SLE pts. CNS impaired in 48% SLE (more likely LAC+, APL+) correlated w BBB (10-30%) leaks. #ACR21, Abstr# 0456 https://t.co/DyUB2TU4pS https://t.co/Sd1tr0BF2H
      RT @uptoTate: Also DESIR cohort: male gender & higher education independently assoc'd w/ lower hazard of Sick Leave

      Dr. Rachel Tate uptoTate

      4 years ago
      Also DESIR cohort: male gender & higher education independently assoc'd w/ lower hazard of Sick Leave (SL.) Older age & higher disease activity assoc'd w/ more SL. AxSpA dz activity & SES play roles in SL predictions. Abs 0380 #ACR21 #RheumNow @RheumNow https://t.co/1lRhDAu7Ug https://t.co/RRG6BeUqvs
      ARRIA Study: Abatacept vs PBO in pre-clincial RA (N98) pts x 6 mos. Showed ABA prevented arthritis (8 vs 35%), improved

      Dr. John Cush RheumNow

      4 years ago
      ARRIA Study: Abatacept vs PBO in pre-clincial RA (N98) pts x 6 mos. Showed ABA prevented arthritis (8 vs 35%), improved MRI inflamm (61 v 31%), fewer D/C (14 vs 43%) - all signif. Further FUV 12 mos off therapy still significant at 18mos #ACR21 Abstract 0455 https://t.co/ZxFUj6KfLT
      RT @KDAO2011: Pearls on Rheum imaging:
      👉CPPD is not erosive
      👉SC joint in OA is common (hard to image)
      👉AC joint

      TheDaoIndex KDAO2011

      4 years ago
      Pearls on Rheum imaging: 👉CPPD is not erosive 👉SC joint in OA is common (hard to image) 👉AC joint is 1st place OA affects shoulders (not GH) 👉Neuropathic OA progress rapidly, look at the TMTs 👉Get more views if you aren't seeing what you need #ACR21 Radiology Bootcamp
      RT @KDAO2011: Another one from Dallas! Congrats, Dr. Limanni! #ACR21 https://t.co/Rs3muuFQKh

      TheDaoIndex KDAO2011

      4 years ago
      Another one from Dallas! Congrats, Dr. Limanni! #ACR21 https://t.co/Rs3muuFQKh
      RT @RichardPAConway: Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need co

      Richard Conway RichardPAConway

      4 years ago
      Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
      RT @rheum_cat: Plenary I

      0454 LN mortality in the US & disparities using CDC WONDER data 1999-2019

      "LN mortality

      Rheum Cat rheum_cat

      4 years ago
      Plenary I 0454 LN mortality in the US & disparities using CDC WONDER data 1999-2019 "LN mortality exhibited profound disparities by race/ethnicity and place of residence" https://t.co/UtMzaiL14D #ACR21 https://t.co/C3fuq8anvR
      RT @Janetbirdope: #ClinicalPearl What lasts longer/⬆️retention in sero+ RA: Abatacept or TNFi or JAKi? #ACR21 abst#

      Janet Pope Janetbirdope

      4 years ago
      #ClinicalPearl What lasts longer/⬆️retention in sero+ RA: Abatacept or TNFi or JAKi? #ACR21 abst#0463 @RheumNow Adjusting for confounding incl line of Rx / past bio Rx, #abatacept wins. But data not stratified for bio naive or exposed. Not sure if that would alter results https://t.co/1dEQncwPQF
      RT @ERheumat: #ACR21 #ACR2021 #ACRLive
      wonderful slide set to explain the spinal phytes https://t.co/5SxN7GeDzh

      EnvisionRheumat ERheumat

      4 years ago
      #ACR21 #ACR2021 #ACRLive wonderful slide set to explain the spinal phytes https://t.co/5SxN7GeDzh
      #ACR21 Convergence Begins! Tune into our latest podcast where Dr. Cush reviews the news, and kicks off ACR21 learning a

      Dr. John Cush RheumNow

      4 years ago
      #ACR21 Convergence Begins! Tune into our latest podcast where Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting. https://t.co/UnFiUR91vB https://t.co/NxVzeQbP4H
      RT @synovialjoints: Factors that predict trajectories of radiographic progression in #axialspondyloarthritis 4 major pat

      Dr. Antoni Chan synovialjoints

      4 years ago
      Factors that predict trajectories of radiographic progression in #axialspondyloarthritis 4 major patterns in the PSOAS cohort. Male gender, longer disease duration, raised CRP and smoking associated with higher spinal progression @RheumNow #ACR21 Abst#450 https://t.co/PvDE7T0MZp
      RT @DrPetryna: Abst 0450 #ACR21 @RheumNow PSOAS cohort 4 trajectories of radiographic progression in AS: Non-progressors

      Olga Petryna DrPetryna

      4 years ago
      Abst 0450 #ACR21 @RheumNow PSOAS cohort 4 trajectories of radiographic progression in AS: Non-progressors 37%, late-progressors 26%, early-progressors 19%, rapid-progressors 18%.⬆️ disease burden: male, longer disease duration & smoking . ⬆️eCRP=higher disease progression https://t.co/wUdBNzJPy0
      ×